Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis.
The specific mechanisms of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) pathogenesis remain unknown. In the present study we investigated the differences between NAFL and NASH in terms of liver lipid metabolites and serum lipoprotein. In all, 104 Japanese subjects (50 men and 54 postmenopausal women) with histologically verified NAFL disease (NAFLD) (51 with NAFL, 53 with NASH) were evaluated; all diagnoses were based on liver biopsy findings and the proposed diagnostic criteria. To investigate the differences between NAFL and NASH in humans, we carefully examined (1) lipid inflow in the liver, (2) lipid outflow from the liver, (3) very-low-density lipoprotein (VLDL) synthesis in the liver, (4) triglyceride (TG) metabolites in the liver, and (5) lipid changes and oxidative DNA damage. Most of the hepatic lipid metabolite profiles were similar in the NAFL and NASH groups. However, VLDL synthesis and lipid outflow from the liver were impaired, and surplus TGs might have been produced as a result of lipid oxidation and oxidative DNA damage in the NASH group.


CONCLUSIONS
A growing body of literature suggests that a deterioration in fatty acid oxidation and VLDL secretion from the liver, caused by the impediment of VLDL synthesis, might induce serious lipid oxidation and DNA oxidative damage, impacting the degree of liver injury and thereby contributing to the progression of NASH. Therefore, dysfunctional VLDL synthesis and release may be a key factor in progression to NASH.
Fujita
Koji
K
Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Nozaki
Yuichi
Y
Wada
Koichiro
K
Yoneda
Masato
M
Fujimoto
Yoko
Y
Fujitake
Mihoyo
M
Endo
Hiroki
H
Takahashi
Hirokazu
H
Inamori
Masahiko
M
Kobayashi
Noritoshi
N
Kirikoshi
Hiroyuki
H
Kubota
Kensuke
K
Saito
Satoru
S
Nakajima
Atsushi
A
D000328:Adult; D002352:Carrier Proteins; D004249:DNA Damage / Q000502:physiology; D005234:Fatty Liver / Q000378:metabolism*; D005260:Female; D006801:Humans; D008079:Lipoproteins, VLDL / Q000096:biosynthesis* / Q000097:blood; D008099:Liver / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D047493:PPAR alpha / Q000096:biosynthesis; D000070778:Perilipin-1; D010750:Phosphoproteins / Q000096:biosynthesis; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
D002352:Carrier Proteins; D008079:Lipoproteins, VLDL; D047493:PPAR alpha; D000070778:Perilipin-1; D010750:Phosphoproteins; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride